MCID: GST037
MIFTS: 53

Gastroparesis

Categories: Gastrointestinal diseases, Metabolic diseases, Rare diseases

Aliases & Classifications for Gastroparesis

MalaCards integrated aliases for Gastroparesis:

Name: Gastroparesis 12 52 54 43 15 17 71
Delayed Gastric Emptying 52
Gastroparesis Syndrome 12
Gastroparalysis 12
Gastric Atonia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:11914
ICD9CM 34 536.3
MeSH 43 D018589
NCIt 49 C80512
SNOMED-CT 67 77164002
ICD10 32 K31.84
UMLS 71 C0152020

Summaries for Gastroparesis

NIH Rare Diseases : 52 Gastroparesis , or delayed gastric emptying, is a disorder where the food does not move or moves very slowly from the stomach to the small intestine . In gastroparesis, the muscles of the stomach do not work well and digestion takes an abnormally long time. Symptoms of gastroparesis include bloating, nausea, vomiting, weight loss due to poor absorption of nutrients, early fullness while eating meals, heartburn, and abdominal pain. Complications can occur including dehydration, electrolyte abnormalities, blood sugar abnormalities, malnutrition, vitamin deficiencies, stomach ulcers , gastroesophageal reflux , esophagitis , small bowel bacterial overgrowth , and metabolic bone disease. In rare cases, food that is poorly digested can collect in the stomach and form a bezoar, a mass of undigested material that can cause a blockage in the gastrointestinal tract. Gastroparesis is more common in people with diabetes and those who have had recent stomach or intestinal surgery. Other causes include infections, hormonal disorders like hypothyroidism, connective tissue disorders like scleroderma , autoimmune conditions , neuromuscular diseases , psychological conditions, and eating disorders. In some cases, the cause is not known (idiopathic). Diagnosis is made on the basis of a radiographic gastric emptying test . Treatment may include dietary modifications such as adjusting the timing and size of meals, consuming more liquid-based meals, or avoiding foods that are more difficult to digest (such as fatty foods, or foods with too much fiber). Other treatments may include endoscopic procedures to break the bezoar apart and remove it, feeding tubes, surgery, placement of an electrical stimulator , and medication such as metoclopramide , domperidone, erythromycin and cisapride . With proper management many people with gastroparesis can live a relatively normal life. However, others may not tolerate treatment and may experience significant complications, a decreased quality of life, and reduced survival.

MalaCards based summary : Gastroparesis, also known as delayed gastric emptying, is related to idiopathic gastroparesis and autonomic neuropathy, and has symptoms including ophthalmoplegia, hemiplegia and signs and symptoms, digestive. An important gene associated with Gastroparesis is MLN (Motilin), and among its related pathways/superpathways are Peptide ligand-binding receptors and Dopamine-DARPP32 Feedback onto cAMP Pathway. The drugs Glucagon and Levodopa have been mentioned in the context of this disorder. Affiliated tissues include testes, lung and colon, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Gastroparesis (gastro- from Ancient Greek ?????? - gaster, "stomach"; and -paresis, ??????? - "partial... more...

Related Diseases for Gastroparesis

Diseases related to Gastroparesis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 389)
# Related Disease Score Top Affiliating Genes
1 idiopathic gastroparesis 32.2 MRC1 HMOX1 GIP GHSR GHRL
2 autonomic neuropathy 31.2 MLNR MLN GAST CCK
3 diabetic autonomic neuropathy 31.0 MLNR MLN GAST
4 pylorospasm 31.0 MLNR MLN
5 tardive dyskinesia 30.9 DRD3 DRD2 CYP2D6
6 gastroesophageal reflux 30.6 MLN GHRL GAST DRD2 CCK
7 pyloric stenosis 30.4 SST NOS1 MLN GAST
8 peptic ulcer disease 30.4 SST GHRL GAST
9 small cell cancer of the lung 30.3 SST GAST CCK
10 atrophic gastritis 30.2 SST GHRL GAST
11 eating disorder 30.1 GHRL DRD3 DRD2 CCK
12 duodenal ulcer 30.1 SST MLN GAST CCK
13 gastrointestinal system disease 30.1 MLN GHRL GAST CCK
14 cholelithiasis 30.0 SST GAST CCK
15 mucositis 30.0 HTR3A GHRL ABCB1
16 gallbladder disease 29.9 SST MLN CCK
17 duodenogastric reflux 29.9 SST MLN GAST CCK
18 irritable bowel syndrome 29.8 SST MLN HTR3A GHRL CCK
19 pain agnosia 29.8 HTR3A CYP2D6 CCK
20 intestinal obstruction 29.8 SST MLNR MLN GHRL ANO1
21 tetrahydrobiopterin deficiency 29.7 TH NOS1
22 biliary dyskinesia 29.7 SST CCK
23 ileus 29.7 SST MLN GHSR GHRL CCK
24 bulimia nervosa 29.7 HTR3A GHRL DRD2 CCK
25 mood disorder 29.7 TH HTR3A DRD3 DRD2
26 leptin deficiency or dysfunction 29.7 GIP GHRL CCK
27 sexual disorder 29.6 NOS1 HTR3A DRD2 CYP3A4 CYP2D6
28 migraine with or without aura 1 29.5 NOS1 HTR3A DRD3 DRD2 CYP3A4 CYP2D6
29 hyperglycemia 29.5 SST GIP GHRL CCK
30 diarrhea 29.2 SST MLN HTR3A GAST CYP3A4 CYP2D6
31 constipation 29.1 TH SST NOS1 MLNR MLN HTR3A
32 alcohol dependence 29.1 TH HTR3A GHRL DRD3 DRD2 CCK
33 dumping syndrome 28.9 SST MLN GIP GHRL GAST CCK
34 anxiety 28.8 TH HTR3A DRD3 DRD2 CYP3A4 CYP2D6
35 parkinson disease, late-onset 28.7 TH NOS1 HTR3A HMOX1 DRD3 DRD2
36 diabetes mellitus 28.5 TH SST MLN HMOX1 GIP GHRL
37 diabetes mellitus, noninsulin-dependent 27.6 TH SST HMOX1 GIP GHRL DRD2
38 stomach disease 11.6
39 brittle diabetes 11.6
40 galactorrhea 10.6 DRD2 CYP2D6
41 codeine toxicity 10.6 CYP2D6 ABCB1
42 rectum neuroendocrine neoplasm 10.5 SST GAST
43 gastrointestinal neuroendocrine benign tumor 10.5 SST GAST
44 idiopathic corneal edema 10.5 DRD3 DRD2
45 non-functioning pancreatic endocrine tumor 10.5 SST GAST
46 hypertrophy of tongue papillae 10.5 CYP3A4 CYP2D6
47 gastric neuroendocrine neoplasm 10.5 SST GAST
48 polysubstance abuse 10.5 DRD3 DRD2
49 duodenal gastrinoma 10.5 SST GAST
50 pancreatic cholera 10.5 SST GAST

Graphical network of the top 20 diseases related to Gastroparesis:



Diseases related to Gastroparesis

Symptoms & Phenotypes for Gastroparesis

UMLS symptoms related to Gastroparesis:


ophthalmoplegia, hemiplegia, signs and symptoms, digestive, lassitude, persistent vomiting

GenomeRNAi Phenotypes related to Gastroparesis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00381-A-1 9.32 GHSR HTR3A MLN
2 Decreased viability GR00381-A-2 9.32 GHSR
3 Decreased viability GR00381-A-3 9.32 GHSR HTR3A MLN
4 Decreased viability GR00402-S-2 9.32 GHSR HTR3A MLN

MGI Mouse Phenotypes related to Gastroparesis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.14 ABCB1 ANO1 DRD2 DRD3 GHRL GHSR
2 digestive/alimentary MP:0005381 10.07 ABCB1 ANO1 DRD2 DRD3 GAST GHRL
3 homeostasis/metabolism MP:0005376 10.06 ABCB1 ANO1 CCK DRD2 DRD3 GAST
4 growth/size/body region MP:0005378 10.03 ABCB1 ANO1 DRD2 DRD3 GHSR GIP
5 endocrine/exocrine gland MP:0005379 9.97 ABCB1 CCK DRD2 GAST GHRL HMOX1
6 no phenotypic analysis MP:0003012 9.5 ABCB1 CCK DRD2 GHSR NOS1 SST
7 renal/urinary system MP:0005367 9.17 ANO1 CCK DRD2 DRD3 HMOX1 HTR3A

Drugs & Therapeutics for Gastroparesis

Drugs for Gastroparesis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 245)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Glucagon Approved Phase 4 16941-32-5
2
Levodopa Approved Phase 4 59-92-7 6047
3
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
4
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
5
Apomorphine Approved, Investigational Phase 4 58-00-4, 41372-20-7 6005
6
Trimethobenzamide Approved, Investigational Phase 4 138-56-7 5577
7
Carbidopa Approved Phase 4 28860-95-9 34359
8
Linaclotide Approved Phase 4 851199-59-2 65351
9
Bismuth subsalicylate Approved, Vet_approved Phase 4 14882-18-9 53629521
10
Loperamide Approved Phase 4 53179-11-6 3955
11
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
12
Ticagrelor Approved Phase 4 274693-27-5 9871419
13
Cangrelor Approved Phase 4 163706-06-7 9854012
14
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
15
Haloperidol Approved Phase 4 52-86-8 3559
16
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
17
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
18 Mosapride Investigational Phase 4 112885-41-3
19 Calcium, Dietary Phase 4
20 Chelating Agents Phase 4
21 Anticoagulants Phase 4
22 Pharmaceutical Solutions Phase 4
23 Protective Agents Phase 4
24 Antiparkinson Agents Phase 4
25 Dihydroxyphenylalanine Phase 4
26 Proton Pump Inhibitors Phase 4
27 Dopamine agonists Phase 4
28 Carbidopa, levodopa drug combination Phase 4
29 Emetics Phase 4
30 Trace Elements Phase 4
31 Micronutrients Phase 4
32 Vitamins Phase 4
33 Antioxidants Phase 4
34 Cathartics Phase 4
35 Laxatives Phase 4
36
Bismuth Phase 4 7440-69-9 16682734 105143
37 Antidiarrheals Phase 4
38 Polyethylene glycol 3350 Phase 4
39 Acetylcholine Release Inhibitors Phase 4
40 Botulinum Toxins Phase 4
41 abobotulinumtoxinA Phase 4
42 Cholinergic Agents Phase 4
43 Botulinum Toxins, Type A Phase 4
44 Platelet Aggregation Inhibitors Phase 4
45 Purinergic P2Y Receptor Antagonists Phase 4
46 Antiemetics Phase 4
47 Gastrointestinal Agents Phase 4
48 Neurotransmitter Agents Phase 4
49 Dopamine Agents Phase 4
50 Dopamine Antagonists Phase 4

Interventional clinical trials:

(show top 50) (show all 326)
# Name Status NCT ID Phase Drugs
1 Prucalopride Versus Placebo in Functional Dyspepsia With Delayed Gastric Emptying Unknown status NCT02510976 Phase 4 prucalopride;placebo
2 Impairment of Gastric Emptying During Acute Phase of Myocardial Infarction. Impact on Oral Antiplatelet Treatment Efficacy. The GASTRIM Study. Unknown status NCT02251249 Phase 4 Paracetamol concentration time curve from 0 to 120 min
3 Glucagon Like Peptides Receptors Expression in the Stomach of Diabetes Type 2 Unknown status NCT00473733 Phase 4
4 Effects and Mechanism of Mosapride Citrate on Diabetic Gastroparesis Unknown status NCT02264587 Phase 4 Mosapride;domperidone
5 Pharmacokinetics of Immediate-Release vs. Delayed-Release Omeprazole in Patients With Heartburn Associated With Gastroparesis Completed NCT00492622 Phase 4 Immediate-release omeprazole;Delayed-release omeprazole
6 Effect of Proton Pump Inhibitor on Gastric Emptying and Satiety Function in Patients With Functional Dyspepsia Completed NCT00951431 Phase 4 Esomeprazole;Placebo
7 A Phase 4, Open-Label, Efficacy and Safety Study of Apokyn® for Rapid and Reliable Improvement of Motor Symptoms in Parkinson Disease Subjects With Delayed Onset of L-Dopa Action Completed NCT01770145 Phase 4 APOKYN;L-dopa;Trimethobenzamide
8 Single-dose Linaclotide for Capsule Endoscopy Preparation Completed NCT02465385 Phase 4 Linaclotide
9 A Prospective Study Comparing Urgent Video Capsule Endoscopy With Urgent Double-balloon Enteroscopy in Patients With Massive Overt Obscure Gastrointestinal Bleeding Completed NCT01654770 Phase 4
10 PEG-Electrolyte Solution (FORTRANS®) With Mentholyptus Drops (Halls®) Versus Reduced Volume Ascorbic Acid Supplemented PEG-Electrolyte (MoviPrep®) in Colonoscopy Preparation: A Randomised Controlled Study Completed NCT01788709 Phase 4
11 Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy for Periampullary Tumors: a Prospective, Randomized, Controlled Clinical Trial Recruiting NCT01642875 Phase 4
12 Reduction of Postoperative Gastrointestinal Dysmotility Following Total Laparoscopic Hysterectomy: a Randomized Control Trial. Recruiting NCT03800745 Phase 4 Colace 100Mg Capsule;Miralax
13 Botulinum Toxin Pyloroplasty to Reduce Postoperative Nausea and Vomiting After Sleeve Gastrectomy Enrolling by invitation NCT03701919 Phase 4 Botulinum toxin pyloroplasty;Normal saline pyloric injection
14 Platelet Inhibition With Cangrelor in Comatose Survivors of Out-of-hospital Cardiac Arrest Undergoing Primary Percutaneous Coronary Intervention Not yet recruiting NCT04005729 Phase 4 Cangrelor 50 MG
15 Double-Blind, Randomized, Placebo-Controlled Trial to Assess Efficacy and Safety of R051619 (Cisapride 10 mg Q.I.D.) Versus Placebo for the Improvement of Symptoms Associated With Exacerbations of Gastroparesis, After Failure of Other Treatments, in Patients With Diabetes Mellitus Terminated NCT01286090 Phase 4 Cisapride;Placebo
16 An Open-label Pilot Trial to Assess the Effect of Tegaserod on Improvement of Gastric Emptying in Patients With Diabetic Gastroparesis and Upper Gastrointestinal Symptoms Terminated NCT00390975 Phase 4 Tegaserod
17 Double-Blind, Randomized, Placebo-Controlled Trial To Assess Efficacy And Safety Of R051619 (Cisapride 10 mg q.i.d.) Versus Placebo For The Improvement Of Symptoms Associated With Exacerbations Of Idiopathic Gastroparesis, After Failure Of Other Treatment Options Terminated NCT01281540 Phase 4 Cisapride;Placebo
18 Enterra Therapy Gastric Stimulation System Terminated NCT00556166 Phase 4
19 Haloperidol vs Conventional Therapy for Gastroparesis Terminated NCT02057549 Phase 4 Haloperidol;Conventional Therapy
20 Daily Tadalafil and Gastric Emptying Time in Diabetic Gastroparesis Withdrawn NCT01326117 Phase 4 tadalafil
21 Prospective Randomized Double-blind Study of Incisional Local Anesthesia in Laparoscopic Surgery (Ketorolac Versus Normal Saline) Withdrawn NCT01374828 Phase 4 Ketolorac
22 A Randomized Controlled Trial of Gastric Meal With and Without Prior Jejunal Feeding on GI Symptoms and Response in Patients With Diabetic Gastro-enteropathy, Diabetic Controls and Healthy Volunteers Withdrawn NCT00944593 Phase 4
23 Comparison Between Antecolic and Retrocolic Gastrointestinal Reconstruction in Delayed Gastric Emptying After Pancreaticoduodenectomy: A Prospective Randomized Controlled Multicenter Trial Unknown status NCT01460550 Phase 3
24 Role of Routine Nasogastric Decompression After Subtotal Gastrectomy Unknown status NCT00164918 Phase 3
25 Sancuso® in Patients With Nausea and/or Vomiting From Gastroparesis: An Open Label Study. Unknown status NCT01989221 Phase 3 Sancuso®
26 Effect of Electroacupuncture in Diabetic Patients With Gastroparesis Unknown status NCT00227383 Phase 3
27 Phase 3 Companion Study of Intranasal Metoclopramide in Men With Symptomatic Diabetic Gastroparesis Completed NCT02025751 Phase 3 Metoclopramide Nasal Spray;Placebo Nasal Spray
28 Phase 3 Study of Intranasal Metoclopramide in Women With Symptomatic Diabetic Gastroparesis Completed NCT02025725 Phase 3 Metoclopramide Nasal Spray;Placebo Nasal Spray
29 Double-Blind Placebo-Controlled Cross-Over Design With Wash-Out for Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis Completed NCT00432835 Phase 3
30 Phase III Study for the Significance of Nasogastric Decompression Tube After Curative Distal Gastrectomy for Gastric Cancer Patients Completed NCT00738478 Phase 3
31 Nortriptyline for Idiopathic Gastroparesis: A Multicenter, Randomized, Double-Masked, Placebo-Controlled Trial (NORIG) Completed NCT00765895 Phase 3 Nortriptyline Hydrochloride;Placebo (for nortriptyline)
32 Sellick Maneuver Evaluation in Rapid Sequence Induction of General Anesthesia Non Inferiority Trial Completed NCT02080754 Phase 3
33 Prucalopride Versus Placebo in Gastroparesis: Randomized Placebo-controlled Crossover Trial Completed NCT02031081 Phase 2, Phase 3 Prucalopride;Placebo
34 Magnetic Resonance (MR) Evaluation of the Effect of Erythromycin Upon Gastric and Small Bowel Motility Completed NCT01379183 Phase 2, Phase 3 Erythromycin;Placebo
35 A Randomized, Prospective Tiral on Efficacy and Tolerability of Low-volume Bowel Preparation Methods for Colonoscopy Completed NCT02250196 Phase 3 PEG-Asc;SPMC 2
36 Effects of the Abbreviation of Preoperative Fasting With Carbohydrates and Hydrolized Proteins on the Inflammatory Response and Insulin Resistance After Major Abdominal Operations Completed NCT01563965 Phase 3
37 Aquanet Bowel Cleansing Device Versus Oral Sodium Picosulfate for Pre-endoscopy Bowel Preparation: Propensity Score Analysis for Interventional Effectiveness Evaluation Completed NCT03074448 Phase 3 Sodium Picosulfate
38 Comparison of a Split Dose Bowel Preparation With 2-L Polyethylene Glycol Plus Ascorbic Acid and 1-L Polyethylene Glycol Plus Ascorbic Acid and Bisacodyl Prior to Colonoscopy Completed NCT02980562 Phase 3 Polyethylene Glycols;Bisacodyl
39 A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis Recruiting NCT03426345 Phase 3 Relamorelin;Placebo
40 A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis Recruiting NCT03285308 Phase 3 Relamorelin;Placebo
41 VP-VLY-686-3301: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Iii Study To Assess The Efficacy Of Tradipitant In Relieving Symptoms Of Gastroparesis Recruiting NCT04028492 Phase 3 Tradipitant;Placebo
42 A 52-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis Recruiting NCT03383146 Phase 3 Relamorelin;Placebo
43 Treatment Protocol for the Compassionate Use of Domperidone Recruiting NCT01696734 Phase 3 Domperidone
44 Does the Strengthening of the Pancreas in Distal Pancreatectomy Using Endo GIA Reload Reinforced Reduce the Occurrence of Pancreatic Fistula? Multicenter Randomized Prospective Open Study Recruiting NCT03030170 Phase 3
45 Open-label Extension Study of Relamorelin for the Treatment of Diabetic Gastroparesis Enrolling by invitation NCT03786380 Phase 3 Relamorelin 10 μg
46 A 46-week, Double-blind, Placebo-controlled, Phase 3 Study With a 6-week Randomized-withdrawal Period to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis Enrolling by invitation NCT03420781 Phase 3 Relamorelin;Placebo
47 Use of Hemopatch as a Sealant at the Pancreaticojejunostomy After Pancreatoduodenectomy to Prevent Postoperative Pancreatic Fistula Not yet recruiting NCT03419676 Phase 3
48 Per-oral Endoscopy Pyloromyotomy (G-POEM) in the Treatment of Refractory Diabetic Gastroparesis : Prospective Evaluation of Efficacy Not yet recruiting NCT02927886 Phase 3
49 A Randomized, Placebo/Sham-Controlled, Double-Blind Crossover Study to Assess the Efficacy of Acupuncture in the Treatment of Diabetic Gastroparesis. Suspended NCT00470795 Phase 3
50 Effects of Pulsatile Insulin Delivery on Peripheral Diabetic Neuropathy Terminated NCT00228891 Phase 2, Phase 3

Search NIH Clinical Center for Gastroparesis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Cisapride
Metoclopramide
Metoclopramide Hydrochloride

Cochrane evidence based reviews: gastroparesis

Genetic Tests for Gastroparesis

Anatomical Context for Gastroparesis

MalaCards organs/tissues related to Gastroparesis:

40
Testes, Lung, Colon, Small Intestine, Pancreas, Bone, Liver

Publications for Gastroparesis

Articles related to Gastroparesis:

(show top 50) (show all 2475)
# Title Authors PMID Year
1
Gastroparesis: Quality of Life and Health Care Utilization. 61 52
27775961 2018
2
Psychological controversies in gastroparesis: A systematic review. 61 52
28275310 2017
3
Gastroparesis: A Review of Current Diagnosis and Treatment Options. 61 52
25874755 2015
4
Gastroparesis: approach, diagnostic evaluation, and management. 61 52
21329779 2011
5
Ghrelin and obestatin levels in type 2 diabetic patients with and without delayed gastric emptying. 54 61
19082715 2009
6
Postprandial secretion of ghrelin in hemodialysis patients with and without diabetic nephropathy. 54 61
19776684 2009
7
Ghrelin receptor agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis. 54 61
19298585 2009
8
Actions and therapeutic pathways of ghrelin for gastrointestinal disorders. 54 61
19434096 2009
9
Influence of ghrelin on the gastric accommodation reflex and on meal-induced satiety in man. 54 61
19210631 2009
10
No ghrelin response to oral glucose in diabetes mellitus with gastroparesis. 54 61
18946177 2009
11
Application of ghrelin to gastrointestinal diseases. 54 61
18821473 2008
12
Effects of oral mitemcinal (GM-611), erythromycin, EM-574 and cisapride on gastric emptying in conscious rhesus monkeys. 54 61
17934842 2008
13
Clinical trial: effect of mitemcinal (a motilin agonist) on gastric emptying in patients with gastroparesis - a randomized, multicentre, placebo-controlled study. 54 61
17894654 2007
14
Potential of ghrelin as a therapeutic approach for gastrointestinal motility disorders. 54 61
17011824 2006
15
Ghrelin stimulates gastric emptying and hunger in normal-weight humans. 54 61
16772353 2006
16
Abnormal ghrelin and pancreatic polypeptide responses in gastroparesis. 54 61
16868831 2006
17
Ghrelin gastrokinetic action in patients with neurogenic gastroparesis. 54 61
16426704 2006
18
[The effects of enteral nutrition vs parenteral nutrition on gastric motility and gastroenteric hormones after subtotal gastrectomy: a perspective randomized compared clinical trial]. 54 61
16836917 2006
19
Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses. 54 61
16492694 2006
20
Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study. 54 61
16085693 2005
21
Influence of ghrelin on gastric emptying and meal-related symptoms in idiopathic gastroparesis. 54 61
16225494 2005
22
Novel approaches to the treatment of nausea and vomiting. 54 61
10697661 1999
23
Comparison of metoclopramide and erythromycin in the treatment of diabetic gastroparesis. 54 61
8299441 1993
24
Erythromycin, motilin, and gastroparesis. 54 61
1464218 1992
25
Role of endoscopic functional luminal imaging probe in predicting the outcome of gastric peroral endoscopic pyloromyotomy (with video). 61
32035074 2020
26
Symptomatic gastric involvement in a parastomal hernia: uncommon presentation. 61
30103665 2020
27
Gastric Electrical Stimulation Reduces Refractory Vomiting in a Randomized Crossover Trial. 61
31647902 2020
28
The effects of ulimorelin, a ghrelin agonist, on liquid gastric emptying and colonic transit in humans. 61
32017341 2020
29
Symptom variability throughout the day in patients with gastroparesis. 61
31782211 2020
30
Third Space Endoscopy: Lessons Learnt From a Decade of Submucosal Endoscopy. 61
31851106 2020
31
Central Nervous System Mechanisms of Nausea in Gastroparesis: An fMRI-Based Case-Control Study. 61
31494751 2020
32
Lessons of the month 3: Duodenal perforation after polystyrene sulfonate. 61
31941743 2020
33
Gastrointestinal Dysfunction and Feeding Intolerance in Critical Illness: Do We Need an Objective Scoring System? 61
31912312 2020
34
Pyloric outflow obstruction secondary to sclerosing encapsulating peritonitis in a dog. 61
31667833 2020
35
Elevated Circulating Levels of Motilin are Associated with Diabetes in Individuals after Acute Pancreatitis. 61
30873575 2020
36
Sleeve gastrectomy for treatment of delayed gastric emptying-indications, technique, and results. 61
31956952 2020
37
A Novel Approach in Spinal Cord Stimulation for Enhancing Gastric Motility: A Preliminary Study on Canines. 61
31917917 2020
38
Short-term outcomes of double pyloromyotomy versus single pyloromyotomy at peroral endoscopic pyloromyotomy in treatment of gastroparesis (with video). 61
31958460 2020
39
The First National Prevalence Estimation of Gastroparesis in the United States Using a Large-scale Retrospective Database. 61
31702589 2020
40
Satiety testing in diabetic gastroparesis: Effects of insulin pump therapy with continuous glucose monitoring on upper gastrointestinal symptoms and gastric myoelectrical activity. 61
31574209 2020
41
Mechanism of CNP-mediated DG-PKC and IP4 signaling pathway in diabetic rats with gastric motility disorder. 61
31583569 2020
42
The multifunctional peptide DN-9 produced peripherally acting antinociception in inflammatory and neuropathic pain via μ- and κ-opioid receptors. 61
31444977 2020
43
Pyloric distensibility measurement after gastric surgery: Which surgeries are associated with pylorospasm? 61
31916346 2020
44
[Analysis of the results of ERAS protocol in real-life clinical practice AFTER radical cystectomy (the first prospective multicenter study in Russia)]. 61
32003169 2020
45
Epidemiology and Diagnosis of Gastroparesis in the United States: A Population-based Study. 61
31135630 2020
46
Full-thickness gastric plication with Overstitch endoscopic suturing device for postsurgical chronic gastroparesis. 61
31968373 2020
47
Gastroparesis versus dyspepsia by intragastric meal distribution: new diagnostics and definitions ahead. 61
31928242 2020
48
Prevalence of gastrointestinal disorders having an impact on tablet levothyroxine absorption: should this formulation still be considered as the first-line therapy? 61
31953721 2020
49
Non-Bariatric Roux-en-Y Gastric Bypass. 61
31539302 2020
50
Desmoplastic Small Round Cell Tumor: Long-Term Complications After Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy. 61
30963398 2020

Variations for Gastroparesis

Expression for Gastroparesis

Search GEO for disease gene expression data for Gastroparesis.

Pathways for Gastroparesis

Pathways related to Gastroparesis according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.34 SST MLNR MLN GIP GHSR GHRL
2 12.18 NOS1 KCNH2 DRD3 DRD2
4 11.94 TH SST KCNH2 HTR3A
5 11.89 SST GIP GHSR GHRL DRD2
6
Show member pathways
11.78 TH DRD3 DRD2
7
Show member pathways
11.77 CYP3A4 CYP2D6 ABCB1
8
Show member pathways
11.59 CYP3A4 CYP2D6 ABCB1
9
Show member pathways
11.48 CYP3A4 CYP2D6 ABCB1
10
Show member pathways
11.35 CYP3A4 CYP2D6 ABCB1
11
Show member pathways
11.09 CYP3A4 CYP2D6 ABCB1
12
Show member pathways
11.03 CYP3A4 CYP2D6 ABCB1
13 10.83 CYP3A4 ABCB1
14
Show member pathways
10.79 TH DRD3 DRD2
15 10.75 CYP3A4 ABCB1
16 10.74 CYP2D6 ABCB1
17 10.73 CYP3A4 ABCB1
18 10.55 CYP3A4 ABCB1
19
Show member pathways
10.34 HTR3A CYP3A4 CYP2D6
20 10.32 GAST CCK
21 10.23 TH GHSR GHRL DRD2

GO Terms for Gastroparesis

Cellular components related to Gastroparesis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuronal cell body GO:0043025 9.55 TH SST HTR3A GIP CCK
2 axon GO:0030424 9.35 TH HTR3A GHRL DRD2 CCK
3 dopaminergic synapse GO:0098691 9.26 DRD3 DRD2
4 glutamatergic synapse GO:0098978 9.02 HTR3A GHSR GHRL DRD3 DRD2

Biological processes related to Gastroparesis according to GeneCards Suite gene sharing:

(show top 50) (show all 62)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.3 MLNR HTR3A GIP GHSR GHRL GAST
2 response to hypoxia GO:0001666 9.94 TH NOS1 HMOX1 DRD2
3 locomotory behavior GO:0007626 9.88 TH DRD3 DRD2
4 memory GO:0007613 9.88 TH GIP CCK
5 cellular response to growth factor stimulus GO:0071363 9.85 TH NOS1 HTR3A
6 excitatory postsynaptic potential GO:0060079 9.85 HTR3A GHRL DRD2
7 response to nutrient levels GO:0031667 9.85 TH GIP GHRL
8 response to hormone GO:0009725 9.84 NOS1 GHSR GHRL
9 visual learning GO:0008542 9.81 DRD3 DRD2 CCK
10 response to nicotine GO:0035094 9.8 TH HMOX1 DRD2
11 response to cocaine GO:0042220 9.77 HTR3A DRD3 DRD2
12 positive regulation of multicellular organism growth GO:0040018 9.77 GHSR GHRL DRD2
13 response to amphetamine GO:0001975 9.76 TH DRD3 DRD2
14 response to ethanol GO:0045471 9.76 TH HTR3A DRD3 DRD2
15 negative regulation of tumor necrosis factor secretion GO:1904468 9.73 GHSR GHRL
16 negative regulation of interleukin-1 beta production GO:0032691 9.73 GHSR GHRL
17 negative regulation of voltage-gated calcium channel activity GO:1901386 9.73 DRD3 DRD2
18 oxidative demethylation GO:0070989 9.73 CYP3A4 CYP2D6
19 prepulse inhibition GO:0060134 9.72 DRD3 DRD2
20 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.72 DRD3 DRD2
21 behavioral response to ethanol GO:0048149 9.72 DRD3 DRD2
22 dopamine metabolic process GO:0042417 9.72 DRD3 DRD2
23 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.72 DRD3 DRD2
24 neurotransmitter biosynthetic process GO:0042136 9.71 TH NOS1
25 positive regulation of renal sodium excretion GO:0035815 9.71 DRD3 DRD2
26 actin polymerization or depolymerization GO:0008154 9.71 GHSR GHRL
27 G protein-coupled receptor internalization GO:0002031 9.71 DRD3 DRD2
28 response to acidic pH GO:0010447 9.7 SST GIP
29 positive regulation of growth GO:0045927 9.7 GHSR GHRL
30 regulation of potassium ion transport GO:0043266 9.7 DRD3 DRD2
31 positive regulation of growth hormone secretion GO:0060124 9.69 GHRL DRD2
32 negative regulation of tumor necrosis factor biosynthetic process GO:0042536 9.69 GHSR GHRL
33 negative regulation of appetite GO:0032099 9.69 GHSR CCK
34 adult feeding behavior GO:0008343 9.68 GHSR GHRL
35 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.68 DRD3 DRD2
36 negative regulation of interleukin-6 biosynthetic process GO:0045409 9.68 GHSR GHRL
37 heterocycle metabolic process GO:0046483 9.66 CYP3A4 CYP2D6
38 drug catabolic process GO:0042737 9.66 CYP3A4 CYP2D6
39 growth hormone secretion GO:0030252 9.65 GHSR GHRL
40 monoterpenoid metabolic process GO:0016098 9.65 CYP3A4 CYP2D6
41 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.63 DRD3 DRD2
42 response to drug GO:0042493 9.63 TH SST GIP DRD3 DRD2 ABCB1
43 negative regulation of dopamine receptor signaling pathway GO:0060160 9.62 DRD3 DRD2
44 regulation of transmission of nerve impulse GO:0051969 9.62 GHSR GHRL
45 regulation of neurotransmitter uptake GO:0051580 9.61 DRD3 DRD2
46 positive regulation of appetite GO:0032100 9.61 GHSR GHRL
47 negative regulation of insulin secretion GO:0046676 9.61 GHSR GHRL DRD2
48 regulation of gastric motility GO:1905333 9.58 GHSR GHRL
49 negative regulation of blood pressure GO:0045776 9.58 NOS1 DRD3 DRD2
50 positive regulation of small intestine smooth muscle contraction GO:1904349 9.57 GHSR GHRL

Molecular functions related to Gastroparesis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.88 TH NOS1 HMOX1 CYP3A4 CYP2D6
2 drug binding GO:0008144 9.61 DRD3 DRD2 CYP2D6
3 monooxygenase activity GO:0004497 9.54 TH CYP3A4 CYP2D6
4 hormone binding GO:0042562 9.46 MLNR GHSR
5 heme binding GO:0020037 9.46 NOS1 HMOX1 CYP3A4 CYP2D6
6 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.4 DRD3 DRD2
7 dopamine neurotransmitter receptor activity GO:0004952 9.32 DRD3 DRD2
8 tetrahydrobiopterin binding GO:0034617 9.26 TH NOS1
9 dopamine binding GO:0035240 9.13 TH DRD3 DRD2
10 hormone activity GO:0005179 9.1 SST MLN GIP GHRL GAST CCK

Sources for Gastroparesis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....